LEE011 for Patients With CDK4/6 Pathway Activated Tumors (SIGNATURE)
Condition Tumors With CDK4/6 Pathway Activation Estimated Enrollment: 106 Age Group: 18 Years and older (Adult, Senior) Gender: All Study Type: Interventional Study Design Allocation: Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment Study ID Numbers: CLEE011XUS03 Study First Received: July 9, 2014 Last Updated: November 27, 2016 Estimated Primary Completion Date: April 2018 Primary Outcome Measures: Clinical benefit rate associated with LEE011 treatment|Overall Response (OR) of Partial Response (PR) or greater|Progression Free Survival (PFS)|Overall Survival (OS)|Duration of Response (DOR)|Safety and tolerability Sponsors and Collaborators: Novartis Pharmaceuticals|Novartis Result Received: No Study Results Posted Website Link: https://ClinicalTrials.gov/show/NCT02187783...
Continue reading